EICHORPublic-registry site landscape for NCT04985968, “The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis”, a Ulcerative Colitis study sponsored by InDex Pharmaceuticals. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT04985968 (registry record) |
| Study title | The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis |
| Official title | A Randomised Double-Blind Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Cobitolimod as an Induction and Maintenance Therapy in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis |
| Sponsor | InDex Pharmaceuticals |
| Condition(s) | Ulcerative Colitis |
| Phase | PHASE3 |
| Listed sites | 203 |
| Site countries | United States, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Canada, Croatia, Denmark, France, Georgia, Germany |
Patient-friendly overview of this study: eichor.com/study/NCT04985968.
Eichor generates a preliminary site-risk snapshot for NCT04985968 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Ulcerative Colitis trials
← Eichor home · All tracked trials · Ulcerative Colitis studies · Weekly briefs
